Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of BIO-B will - over the next 2 Weeks and hit - by . In that time frame, BIO-B's share price is expected to range between - and -.
BearishAverageBullishBIO-B shares remained flat 0 in Wednesday, July 30, 2025's trading session, starting and closing at a previous close of $247.05 to move at $247.05. The stock demonstrated notable intraday movement (see BIO-B's key stats for a full breakdown), fluctuating between $247.05 and $247.05, a 0 trading range. While recent weeks have seen some volatility, BIO-B has managed to secure a -1.21% drop over the past 2 weeks. The neutral price movement was accompanied by decreased trading volume, with approximately 5 shares changing hands, 242 fewer than the previous session. This amounted to $1.24K in total market activity.
Will BIO-B Continue Its Trend?
According to analyst ratings and projections for BIO-B, Bio-Rad Laboratories, Inc. shares are anticipated to remain stable by -, potentially reaching - per share by January 1, 1970. Short-term technical indicators for BIO-B currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 27 negative trading days within the past 30 sessions. Based on the BIO-B stock forecast, now is not the best time to buy BIO-B stock because its current trading price is - our predicted value, hinting at a possible . For deeper insights, view our sentiment analysis on BIO-B covering social and institutional perspectives.
BIO-B Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into BIO-B's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 22.17% to 36.14%) suggest the stock is experiencing strong bearish momentum. The 50-day RSI, at 36.33%, hints at potential weakness developing in the medium term. Additionally, the 100-day RSI, at 36.06%, signals a bearish bias in the long-term trend. Insights into BIO-B's shareholder base show how institutional investors are positioning themselves during these momentum shifts